A perspective on integrating digital pathology, proteomics, clinical data and AI analytics in cancer research.

Nearly 40 % of individuals will be diagnosed with cancer in their lifetime, translating to an estimated 20 million new cases annually. Despite remarkable therapeutic advances, only 15-20 % of patients achieve durable responses to immunotherapy, and the high cost of treatment (illustrated by immune checkpoint inhibitors like pembrolizumab and nivolumab, totaling roughly $191,000 per year) remains a formidable global challenge. The convergence of digital pathology, high-throughput molecular profiling, and advanced computational strategies has the potential to transform cancer research. By integrating high-resolution morphological data with proteomic, transcriptomic, and spatial molecular insights, we can elucidate the complex interplay between tumor cells and their microenvironment. In this perspective, we review how emerging techniques, from AI-driven image analysis to deep visual proteomics, can accelerate biomarker discovery, refine patient stratification, and ultimately improve clinical outcomes. We illustrate these principles with a case study in melanoma, where the integration of digital pathology and deep proteomic profiling uncovered a molecular signature predictive of recurrence in early-stage disease. As these technologies evolve, we foresee a future of precision oncology characterized by the seamless integration of morphological, clinical, and molecular data enabled by AI-driven analytics. SIGNIFICANCE: This perspective represents a pivotal step toward transforming cancer research by bridging the gap between traditional histopathological evaluation and modern molecular analytics. By integrating digital pathology with spatial proteomics and advanced AI-driven analytics, our approach provides a multidimensional view of tumor biology that captures both morphological nuances and molecular heterogeneity. This comprehensive framework not only enhances our understanding of the tumor microenvironment but also facilitates the discovery of robust biomarkers for disease recurrence and therapeutic response. Ultimately, our findings underscore the potential of precision oncology to tailor treatment strategies to individual patient profiles, thereby improving clinical outcomes and guiding the next generation of personalized cancer care.